Reportable Values for Out-of-Specification Test Results

FDA Reports on Status of Postmarketing Requirements and Postmarketing Commitments

Novartis’ Radioligand Therapy Gains FDA Nod for Pediatric Patients

Navigating an Uncertain Regulatory Environment for mRNA-based Products